153
Participants
Start Date
April 21, 2021
Primary Completion Date
June 7, 2023
Study Completion Date
June 8, 2023
SAF312 Placebo
Topical ocular, suspension eye drops
SAF312
Topical ocular, suspension eye drops
University of Pennsylvania ., Philadelphia
Piedmont Eye Center, Lynchburg
Duke Univ Medical Center Ophthalmology, Durham
Novartis Investigative Site, Jacksonville
Novartis Investigative Site, Coral Springs
Novartis Investigative Site, Miami
Advancing Vision Research LLC, Smyrna
Chattanooga Eye Institute, Chattanooga
Novartis Investigative Site, Memphis
Univ of MI Kellogg Eye Center ., Ann Arbor
Bergstrom Eye Research LLC, Fargo
Novartis Investigative Site, Houston
Novartis Investigative Site, Houston
Novartis Investigative Site, Houston
Lake Travis Eye and Laser Ctr, Lakeway
Stacy R Smith MD PC, Salt Lake City
North Valley Eye Medical Group, Mission Hills
Gordon Schanzlin New Vision Inst, San Diego
NVISION Eye Centers, Newport Beach
Stanford Eye Laser Center, Palo Alto
Rainier Clinical Research Center Inc ., Renton
Periman Eye Institute, Seattle
Tufts Medical Center, Boston
Boston Sight, Needham
Novartis Investigative Site, Sapporo
Novartis Investigative Site, Shinagawa
Novartis Investigative Site, Birmingham
Novartis Investigative Site, Newcastle upon Tyne
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY